On Monday, Autolus Therapeutics plc ADR (NASDAQ: AUTL) was -5.90% drop from the session before settling in for the closing price of $3.73. A 52-week range for AUTL has been $3.06 – $7.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 190.29%. When this article was written, the company’s average yearly earnings per share was at 31.58%. With a float of $236.60 million, this company’s outstanding shares have now reached $266.05 million.
Considering the fact that the conglomerate employs 463 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 52.27%, operating margin of -1518.81%, and the pretax margin is -1845.81%.
Autolus Therapeutics plc ADR (AUTL) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Autolus Therapeutics plc ADR stocks. The insider ownership of Autolus Therapeutics plc ADR is 11.07%, while institutional ownership is 55.99%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 31.58% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
You can see what Autolus Therapeutics plc ADR (AUTL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 88.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.73 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Compared to the last year’s volume of 1.42 million, its volume of 3.12 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 38.77%. Additionally, its Average True Range was 0.33.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 20.53%, which indicates a significant increase from 18.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.40% in the past 14 days, which was higher than the 69.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.98, while its 200-day Moving Average is $4.57. Nevertheless, the first resistance level for the watch stands at $3.84 in the near term. At $4.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.34. If the price goes on to break the first support level at $3.34, it is likely to go to the next support level at $3.16. Now, if the price goes above the second support level, the third support stands at $2.84.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
There are 266,094K outstanding shares of the company, which has a market capitalization of 933.84 million. As of now, sales total 1,700 K while income totals -208,380 K. Its latest quarter income was 10,090 K while its last quarter net income were -52,690 K.
